AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
Shots:
- The P-III trial evaluating Imfinzi + Pt-based CT, followed by Imfinzi with Lynparza or Imfinzi alone as maintenance therapy vs Pt-based CT alone in 699 patients at 253 study locations across 22 countries incl. the US, EU, South America & Asia
- The results showed a significant & clinical improvement in PFS, greater benefits were seen with the combination of Lynparza + Imfinzi as maintenance treatment while OS data were immature & favorable trends were reported for both a treatment regimen
- The safety & tolerability profile was consistent with prior clinical trials & the known profile of the individual’s therapies. The company will discuss the results with the regulatory authorities
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
